HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eclipse's minimally-invasive direct coronary artery bypass (MIDCAB) surgery trial receives investigational new device exemption (IDE):

This article was originally published in Clinica

Executive Summary

Eclipse Surgical Technologies has received an IDE from the FDA to begin the first US clinical study of its minimally-invasive approach to transmyocardial revascularisation (TMR). The company's TMR laser will be used in combination with minimally-invasive direct coronary artery bypass surgery (MIDCAB) to treat additional areas of the heart that this surgical technique alone cannot revascularise. MIDCAB uses incisions between the ribs rather than cutting through the sternum. Eclipse, based in Sunnyvale, California, received European approval to affix CE marking to its TMR laser in December.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT083548

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel